Found 7 articles for: "glucagon-like peptide-1 receptor agonist"
Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin Treatment
September 2026 | Volume 25 | Issue 9 | Original Article | 814 | Copyright © September 2026
Background: Antiaging skin treatments are continuously in development to meet the needs of an aging population and counteract cosmetic effects of glucagon-like peptide-1 receptor...
Read MoreGLP-1 Receptor Agonist Paradox in Hair Biology: A Biphasic dWAT–Follicle Signaling Hypothesis
September 2026 | Volume 25 | Issue 9 | Features | 874 | Copyright © September 2026
Improvement of Rosacea With Tirzepatide: A Case Report
August 2026 | Volume 25 | Issue 8 | Case Reports | 749 | Copyright © August 2026
GLP-1 Receptor Agonist Use for Diabetes Mellitus is Associated With Reduced Psoriasis Disease Severity
August 2026 | Volume 25 | Issue 8 | Features | 753 | Copyright © August 2026
Weight Loss and Its Impact on Soft Tissue
May 2026 | Volume 25 | Issue 5 | Original Article | 449 | Copyright © May 2026
Background: Rapid and intentional weight loss can result from bariatric surgery, pharmacologic agents such as glucagon-like peptide-1 receptor agonists, and intensive lifestyle c...
Read MoreThe Safety of GLP1 Receptor Agonist Usage in Mohs Micrographic Surgery Patients
April 2026 | Volume 25 | Issue 4 | Editorials | 394 | Copyright © April 2026
Glucagon-Like Peptide-1 Receptor Agonists Reduce Surgeries and Hospitalizations in Hidradenitis Suppurativa: A Multicenter TriNetX Cohort Study
September 2025 | Volume 24 | Issue 9 | Original Article | 869 | Copyright © September 2025
Background: Hidradenitis suppurativa is a chronic inflammatory skin condition frequently associated with type 2 diabetes mellitus and obesity. Glucagon-like peptide-1 receptor ag...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.